Table 3 The level of 8-oxo-dG in human serum and cytogenetic damage in human lymphocytes in accordance with lycopene plus β-carotene concentration

8-oxo-dG

(A)

0

0.46 ± 0.23

0.32 ± 0.10

0.28 ± 0.10

(ng/mL)

0.1

0.66 ± 0.30

0.52 ± 0.21

0.74 ± 0.35

0.5

0.58 ± 0.30

0.42 ± 0.20

0.48 ± 0.09

2

0.41 ± 0.19

0.34 ± 0.08

0.49 ± 0.17

(B)

0

0.73 ± 0.22

0.45 ± 0.08

0.97 ± 0.46

0.1

0.71 ± 0.21

0.53 ± 0.04

0.76 ± 0.29

0.5

0.45 ± 0.11

0.53 ± 0.12 ^b

1.04 ± 0.21

2

0.63 ± 0.20

0.77 ± 0.30

0.69 ± 0.20

MN

(A)

0

22.10 ± 2.96

17.93 ± 4.45

24.07 ± 4.34

(/1000 BNC)

0.1

22.86 ± 1.93

20.54 ± 1.78

28.91 ± 3.59

0.5

68.98 ± 8.04

54.88 ± 4.87

57.05 ± 8.38

2

281.6 ± 15.6

330.7 ± 26.7

337.9 ± 19.9

(B)

0

20.17 ± 2.97

14.30 ± 3.07

24.94 ± 5.63

0.1

22.43 ± 6.45

20.84 ± 4.32

24.27 ± 3.79

0.5

57.84 ± 7.61

50.06 ± 4.06

53.01 ± 4.19

2

286.6 ± 12.2

300.2 ± 26.7

282.6 ± 17.8

DIC

(A)

0

0

0.18 ± 0.18

0

(/500 metaphase)

0.1

0.92 ± 0.49

0.38 ± 0.23

0.78 ± 0.20

0.5

21.31 ± 1.33

19.93 ± 0.87

21.1 ± 1.71

2

98.72 ± 6.24

93.47 ± 4.32

105.4 ± 7.1

(B)

0

0.19 ± 0.19

0

0.19 ± 0.19

0.1

0.32 ± 0.32

0.58 ± 0.39

0.40 ± 0.24

0.5

18.65 ± 1.86

14.99 ± 1.31 ^a,#

20.86 ± 1.96

2

89.45 ± 6.13

85.64 ± 3.26 ^$

99.73 ± 5.60